12:00 AM
 | 
Jul 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

U300: Phase III data

Top-line data from the open-label, international Phase III EDITION II trial in 811 Type II diabetics showed that once-daily subcutaneous U300 as an add-on to oral antidiabetic drugs met the primary endpoint of non-inferiority to once-daily Lantus insulin glargine as an add-on to oral antidiabetic drugs in reducing HbA1c from baseline to 6 months....

Read the full 256 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >